Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 43Carcinoma, Hepatocellular 41Carcinoma, Non-Small-Cell Lung 17Colorectal Neoplasms 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Sarcoma 11Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Triple Negative Breast Neoplasms 10Lung Neoplasms 10Cholangiocarcinoma 10Esophageal Squamous Cell Carcinoma 9Esophageal Neoplasms 9Osteosarcoma 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Neoplasms 6Head and Neck Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Liver Neoplasms 5Glioma 5Drug-Related Side Effects and Adverse Reactions 4Thyroid Neoplasms 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

apatinib 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2-negative Breast Cancer Brain Metastases × apatinib × Clear all
NCT06418594 2024-12-10

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Beijing 302 Hospital

Phase 2 Recruiting
30 enrolled
Breast

HER2-negative Breast Cancer Brain Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡